hcplive.com
Cure8 news brief
Long-Term Risankizumab Data Show Durable Crohn's, Fistula Outcomes | HCPLive
Medications
Risankizumab
IL-23 inhibitor
Fistula
Conference Abstract
Patients On Biologics
Clinicians
Researchers
Why This Matters
Long-term control of inflammation and healing of draining fistulas are important for people with Crohn’s disease; these FORTIFY OLE analyses suggest durable benefit with risankizumab in responders through several years of follow-up.
Who Should Pay Attention
Adult patients with Crohn’s disease (especially those on or considering biologic/IL‑23 therapy), clinicians managing biologic treatment and fistulizing disease, and researchers studying long-term biologic outcomes.
Study Snapshot
Story typeResearch news
Evidence typeConference abstract
Source depthFull source text
What To Know
These are post hoc analyses of the FORTIFY open-label extension (OLE), not randomized comparisons.
One analysis examined remission and endoscopic outcomes by baseline disease location through 144 weeks and found that clinical and endoscopic measures were maintained or improved over time in colonic and ileocolonic disease and remained generally stable in ileal disease.
A second analysis focused on 73 patients who had draining fistulas at induction baseline and reported rising proportions with no draining fistula over follow-up (reported as-observed up to OLE week 192). The higher-dose 360 mg subgroup consisted of patients who previously required rescue therapy and had smaller evaluable numbers over time.
Keep In Mind
Findings are based on post hoc analyses from an open-label extension of clinical trials presented at a conference; they do not replace randomized trial evidence and apply to patients who responded to induction and continued in the OLE.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationhcplive.com
AuthorsAbigail Brooks, MA
Indexed viaGoogle News
Source typeWeb article
PublishedOct 12, 2026, 2:33 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparative Effectiveness and Safety of Risankizumab vs Ustekinumab in Crohn's Disease: A Real-World Retrospective Cohort Study from Taiwan.
Comparative real-world data may help patients and clinicians weigh expected benefits and risks of risankizumab versus ustekinumab in Crohn’s disease, including effects on steroid-free remission and fistula healing.
Medical Therapies Beyond Infliximab for Perianal Fistulizing Crohn's Disease: Current Evidence and Future Perspectives.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.